An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can
A phase 3 trial of Rinatabart sesutecan, Paclitaxel / nab-paclitaxel, Topotecan in ovarian cancer, run by Genmab, now recruiting.
Overview
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China is a phase 3 interventional study registered as NCT07604766 by Genmab, with 82 participants planned, started 2026-06-26 and due to reach its primary completion in 2027-09. Interventions recorded: Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Shares Rinatabart sesutecan, Pegylated liposomal doxorubicin, Topotecan, Genmab.
- TrialStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or
Shares Rinatabart sesutecan, Genmab, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialStudy to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re
Shares Rinatabart sesutecan, Genmab, Ovarian cancer.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Shares Pegylated liposomal doxorubicin, Topotecan, Gemcitabine, Ovarian cancer.
- TrialA Study of SHR-A1811 in Subjects With Ovarian Cancer
Shares Topotecan, Gemcitabine, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialRAINFOL-01 (Rina-S)
Shares Rinatabart sesutecan, Genmab, Ovarian cancer.
- TrialStudy to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Shares Rinatabart sesutecan, Genmab.
- TrialStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Shares Rinatabart sesutecan, Genmab.